Concepedia

Matthias Ludwig

ML

6

Publications

413

Citations

6

H-Index

2006

Active since

Affiliations

Bayer (United States)(Current)

Bayer (Germany)

Matthias Ludwig is an author at Bayer (United States) specializing in radiation oncology, cancer therapeutics, and medicine.

ORCID

Top concepts

Publications per year

2006–2014

6

Publications

6

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Heike Richly, Bernhard F. Henning, P. Kupsch et al. · Annals of Oncology · 2006 · 142 citations · Full text

, , +8

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Johannes Nagelschmitz, Martin Blunck, Joern Kraetzschmar et al. · Clinical Pharmacology Advances and Applications · 2014 · 126 citations · Full text

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

Heike Richly, Beate Schultheis, Irenäus A. Adamietz et al. · European Journal of Cancer · 2008 · 83 citations

, , +7

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

Dirk Strumberg, Beate Schultheis, Irenäus A. Adamietz et al. · British Journal of Cancer · 2008 · 23 citations · Full text

, , +17

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein

Michael‐Friedrich Boettcher, Roland Heinig, Carsten Schmeck et al. · British Journal of Clinical Pharmacology · 2011 · 20 citations

Rows per page

1–5 of 6